Protocol Ledger

NCT03224767 · Phase II · ACTIVE NOT RECRUITING

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

Interventional Phase II clinical trial protocol NCT03224767 sponsored by Alliance for Clinical Trials in Oncology in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-01-05 Enrollment: 24 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03224767
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)24 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03224767
Protocol FieldVerified Registry Value
NCT IdentifierNCT03224767
Consolidated Lead SponsorAlliance for Clinical Trials in Oncology
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment24 participants (ACTUAL)
Registered Start Date2018-01-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI